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Summary: Elevated phospholipase A2 activities in serum were measured in patients suffering from acute
pancreatitis or various inflammatory diseases. The photometric phospholipase A assay of Hoffmann &
Neumann (Klin. Wochenschr. 67 (1989) 106 — 109) was combined with immunoabsorption by different mono-
clonal antibodies directed against pancreatic phospholipase A2. Pancreatic phospholipase A2 was purified
from human duodenal juice. Monoclonal antibodies were prepared by fusion of spleen cells from immunized
mice with P3X63-Ag8-653 myeloma cells. Samples with phospholipase A2 activity were incubated in mono-
clonal antibody-coated microtitre plates. Phospholipase A2 activities were determined in the monoclonal
antibody-treated samples as well as in control samples. The method allows the determination of the fraction
of human phospholipase A2 isoenzymes in various biological materials. For pancreatic phospholipase A2 the
specific binding capacity was about 60 — 80%, the unspecific binding was 5 — 30%. Practically no cross-
reactivity was seen with partially purified serum phospholipase A2, with recombinant platelet phospholipase
A2, or with the sera of patients with non-pancreatic diseases. In conclusion, the present study confirmed the
presence of pancreatic phospholipase A2 in human duodenal juice and in the ascites of necrotizing pancreatitis.
However, pancreatic isoenzyme was absent in non-pancreatic inflammatory diseases. Therefore, elevated
phospholipase activities in non-pancreatic inflammatory diseases cannot be attributed to the pancreas.
Introduction
Serum phospholipase A2 (EC 3.1.1.4) has long been
assumed to originate exclusively from the pancreas
(for review see 1. c. (1)). More recently, this assumption
has been challenged by our group (1 —4) and other
authors (5—7).
In 1988, Eskolq et al. (6) demonstrated the existence
of two different forms of phospholipase A2 in human
serum using polyclonal antibodies against the pancre-
atic isoenzyme. Their study design, however, did not
unequivocally prove that one of these "isoenzymes"
* This work is part of the doctoral thesis of C. Dosser (Med.
Fakultät of the Ludwig-Maximilians-Universität München,
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was pancreatic phospholipase A2; since phospholi-
pases A2 possess a highly conserved protein structure
(8, 9), polyclonal antibodies against the pancreatic
enzyme might cross-react with structurally related"
isoenzymes. Immuno-reactive proteins have been
found in serum of patients with non-pancreatic ma-
lignant tumours (10) as well as in rat spleen (11). On
the other hand, most phospholipases A2 have a
marked tendency to bind to proteins and surfaces in
an unspecific manner (3, 12, 13), so that antibody-
independent binding artifacts may occur.
The present article describes a practicable combina-
tion of activity measurements based on a photometric
assay (2) and immunoabsorption by different mono-
clonal antibodies. The photometric assay has been
212 Hiefinger-Schindlbeck et al.: Phospholipase A2 isoenzyraes in human body fluids
shown to measure pancreatic and non-pancreatic
phospholipase A2 activity (4,14) and to be equivalent
to radiometric methods (14). The technique allows
the determination of the fraction of human phospho-
lipase A2 isoenzymes, and is suitable for application
to various biological materials.
Materials and Methods
Recombinant human platelet phospholipase A2 (15) was a kind
gift of Biogen Inc., Cambridge MA, USA. The enzyme solution
(0.1 g/1) was diluted 50- to 100-fold with 10 mmol/1 TRIS/HC1
pH 8 containing 20 g/1 bovine serum albumin.
Human pancreatic phospholipase A? was purified from duodenal
juice an described previously (16) by a combination of precip-
itation steps, Hydrophobie and cation exchange chromatogra-
phy.
Human serum phospholipase A2 was prepared from 0.71 pooled
serum of unselected patients of our hospital, using only the
final cation exchange step of the latter purification procedure
with slight modifications: the native serum was diluted 1 :2
with 20 mmol/1 TRIS/HC1 pH 8.4 and the chromatography
was performed in the same buffer. Active fractions eluted with
700 mmol/1 KC1 were pooled, dialysed against KCl-free buffer
and lyophiüzed to dryness after addition of 50 g/1 mannitol.
For the antibody binding experiments, native sera of individual
patients were pooled separately, stored at 4 °C, and diluted with
20 mmol/1 TRIS/HC1 pH 7.5 containing 20 g/1 bovine serum
albumin to give a final activity of 50 to 70 U/l. The underlying
diagnoses were necrotizing pancreatitis (patient A, female, 84
years), severe burns (patient B, male, 42 years), and septicaemia
(patient C, male, 42 years). Further body fluids tested for
antibody binding were native duodenal juice obtained during
pancreas function tests as well as abdominal and pleural exu-
dations of a patient D (male, 55 years) with a necrotizing bout
of chronic pancreatitis.
Monoclonal antibodies directed against pancreatic phospholi-
pase A2 were produced, using purified phospholipase A2 from
human duodenal juice (see above) as an antigen. Balb/c mice,
12 weeks old, were immunized intraperitoneally with 50 g
antigen in complete Freund*s adjuvant. Two booster injections
were given at monthly intervals under the same conditions.
Three days before fusion, an intravenous injection of 50 g
antigen was given in saline without Freunds adjuvant.
Fusion of spleen cells from immunized mice was performed
with P3X63-Ag8-653 myeloma cells, and fused cells were cul-
tivated in RPMI 1640 medium supplemented with fetal calf
serum, volume fraction 0.1,2 mmol/1 L-glutamine and 1 mmol/1
sodium pyruvate, containing 0.1 mmol/1 hypoxanthine and 0.01
mmol/i azaserine as a selective medium.
Hybridoma supernatants were screened for binding to phos-
pholipase A2 adsorbed on microtitre plates (Nunc). Anti-phos-
pholipase-antibodies were detected by sheep anti-mouse-Fcr-
antiserum labelled with horseradish peroxidase. ABTS substrate
was added and the absorbance at 405/455 nm recorded in an
ELISA-reader from Dynatech.
The antibodies were purified either by anion exchange (DE),
cation exchange (Q), or size exclusion chromatography (TSK),
biotinylated and provided as a lyophilized powder.
The following five lots out of eight different antibodies ob-







For our experiments, antibody solutions (10 mg/1) were pre-
pared with buffer A (50 mmol/1 potassium phosphate buffer
pH 7.5 containing 150 mmol/1 NaCl).
Streptavidin-coated microtitre plates (TRSA-SA) as well as the
substrate kit for phospholipase A determination (cat. No.
1056239) were from Boehringer Mannheim, Germany. Other
reagents were: bovine serum albumin from Serva, Heidelberg,
Germany, poly-L-lysine hydrobromide from Sigma, St. Louis,
USA, and the Coomassie protein test kit from Biorad, Ana-
heim, USA. All other reagents were of the highest commercial
quality.
Immunoabsorption assay
for pancreatic phospholipase A2
The photometric activity assay was performed as described (17)
with two exceptions: the fatty acid test kit from Wako Chem-
icals, Neuss, Germany (cat. No. 273-75409) was used as in 1. c.
(2) and pancreatic phospholipase A2 was determined at pH 6.0
instead of 8.0 (16).
For preparation of antibody-coated microtitre plates, 0.2 ml
antibody solution (10 mg/1) were pipetted into each well and
discarded after incubation for 30 min at room temperature. In
order to block non-specific binding sites of the plates a second
incubation was performed with 0.2 ml of poly-L-lysine (0.1 g/1).
The fluid was discarded after 30 min and the wells were rinsed
three times with buffer A. Control plates were prepared using
buffer A instead of antibody solution.
A phospholipase-containing sample (0.1 ml, activity 50—70
U/l) was incubated for 30 min at room temperature. Enzyme
activities were determined at 37 °C in the untreated sample as
well as in the antibody and the control incubation: 0.04 ml
sample were added to 0.2 ml prewarmed substrate solution
(37 °C). After exactly 5 and 20 min, 0.04 ml of the incubation
mixture was transferred to 0.02 ml ice-cold stop solution. For
fatty acid determination, 0.4 ml prewarmed Wako-reagent A
were added to this stop mixture and 10 min thereafter 0.8 ml
reagent B. The absorbance at 546 nm (1 cm path length) was
read after another 10 min and the activity was calculated using
a molar absorbance of 1540 m2/mol (2):
phospholipase A2 (U/l) = (A2omin-A5mi„) x 818
Taking the activity of the untreated sample (u) as 1.0, the
relative activities of the antibody-rtreated samples (a) and the
control samples (c) were calculated. Total, specific, and unspe-
cific binding (TB, SB, UB) were derived from these percent
values by the following formulae:
TB = 1.0 - a
UB == 1.0 - c
SB = TB - UB = c - a
Results
In a first series of experiments, we tested the antigen
binding capacity of the microtitre plates with purified
pancreatic phospholipase A2. Figure 1 shows the re-
sults for those two antibodies which were best suited
for the differentiation between pancreatic and non-
pancreatic phospholipase A2 in biological fluids (see
also tab. 1). Using the antigen solution under the
standard conditions described in the methods section,
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Fig. 1. Binding capacity of two monoclonal antibodies, 2.50.75-
IgG-(TSK)-Bi(X-Osu) (closed triangles) and 2.223.288-
IgG(Q)-Bi(X-Osu) (closed circles) for purified human
pancreatic phospholipase A2. The closed symbols re-
present the fraction of specific binding to the mono-
clonal antibodies, the open circles indicate the fraction
of unspecific binding in the absence of antibody. For
experimental details see methods section.
the specific binding capacity was 0.6 to 0.8 and the
unspecific binding 0.05 to 0.3 (fig. 1). Complete bind-
ing was achieved only at barely detectable sample
activities around 20 U/l (results not shown). As a
compromise, we usually used samples with activities
of 50 to 70 U/l, in order to obtain reasonable binding
rates under optimal measuring conditions. Calculat-
ing a specific activity of 2000 U/mg protein for pan-
creatic phospholipase A2 (16), our results indicate that
each well was capable of binding 1 to 2 ng antigen in
a specific, and 0.5 to 1 ng in an unspecific manner.
In a second series of experiments we tested eight
different biological materials as antigens, using five
different monoclonal antibodies under the conditions
described in the methods section. It is shown (tab. 1)
that the proportion of specific binding ranged from
0.7 to 0.9 with purified pancreatic phospholipase A2,
native duodenal juice or the ascites fluid of a patient
with necrotizing pancreatitis. Lower and less repro-
ducible binding rates around 0.5 were obtained with
a pleural puncture fluid and a serum pool of a patient
with necrotizing pancreatitis. Practically no cross-
reactivity (0 to 0.13) was seen with partially purified
serum phospholipase A2 and the recombinant platelet
enzyme, or with the serum pools of two patients with
non-pancreatic diseases (burn injury, septicaemia).
Although the five monoclonal antibodies behaved in
a rather similar manner, two of them (designated C
and E in the methods section) seemed to be best suited
for the differentiation between pancreatic and non-
pancreatic phospholipase A2 in biological materials
(see tab. 1).
It is of interest that the tendency of the different
phospholipases to bind to the vessel wall in an un-
specific manner was very variable, ranging from 0.03
to 0.35 (tab. 1). The lowest values were obtained with
purified and native pancreatic phospholipases A2 and
the highest rates with recombinant platelet phospho-





























Native duodenal juice 65
Native abdominal exudation 61
(Pat. D)
Native pleural exudation 62
(Pat. D)
Native serum pool/ 48
necrotizing pancreatitis
Native serum pool/severe burns 65







0.82 0.82 0.71 0.77 0.88
0.77 0.83 0.88 0.83 0.85
0.38 0.59 0.66 0.48
0.04
0.71
0.17 0.59 0.24 0.18
0.02 0.13 0.05 0 0
0.01 0 0.07 0.05 0.07
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lipase A2 and two serum pools. The high affinity for
surfaces seemed to be more characteristic for the non-
pancreatic than the pancreatic isoenzyme. Precoating
of microtitre plates with albumin or gelatine instead
of poly-L-lysine did not reduce this unspecificity (re-
sults not shown).
Discussion
The present paper offers a photometric procedure for
characterizing phospholipase A2 isoenzymes in human
body fluids (2, 17). Two different human isoenzymes
classified as type I and type II phospholipase A2 have
been extensively studied: the pancreatic isoenzyme
(type I), which is secreted as an inactive proenzyme
and activated by limited proteolysis (18), and an "in-
flammatory"1 isoenzyme (type II), which is present as
an active protein in human spleen (19), human plate-
lets and arthritic synovial fluid (15). The latter phos-
pholipase is also secreted from cultured liver cells
under the control of interleukines and tumour necrosis
factor and might act as an acute phase protein, which
has been pointed out by Crowl et al. (5) and Matsuda
et al. (19).
Although phospholipases A2 are well known to be
involved in inflammatory processes (4, 7), the discus-
sion about the contribution of different serum iso-
enzymes to pathological states is still controversial.
In acute pancreatitis, it is not clear yet wether the
activation of the pancreatic isoenzyme by tryptic au-
todigestion (18) plays a significant role in the induc-
tion of intra- and extra-pancreatic inflammation and
necrosis (1, 18). Many phospholipases A2, e.g. those
from snake and insect venoms, are known to be highly
toxic (20). The appearance of active phospholipase(s)
in blood has been found to be correlated with lethality
(4). The evaluation of their possible pathogenetic role
is of great scientific and medical interest.
Antibody-based techniques have been used by several
investigators in order to prove the presence of pan-
creatic phospholipase A2 in human blood and other
body fluids (10, 21 -23). Since these radio- and fluo-
roimmunoassays measured the protein mass rather
than the activity, it could not be decided whether they
detected the active enzyme or inactive precursors and
degradation products. Eskola et-al. (6) used antibody-
coated tubes in order to measure specifically the ac-
tivity of the pancreatic isoenzyme by an immunoab-
sorption assay. They demonstrated the coexistence of
both pancreatic and non-pancreatic phospholipase A2
activity in serum of patients with pancreatitis.
Using the modified test system described in this ar-
ticle, we have demonstrated the expected presence of
pancreatic phospholipase A2 in duodenal juice and in
the ascites of a patient with necrotizing pancreatitis.
Furthermore, we were able to show that the pancre-
atic isoenzyme was absent from the pooled sera of
two patients with non-pancreatic inflammatory dis-
eases. It is of interest that in the latter cases unspecific
binding of the enzyme was much higher than specific
binding. This phenomenon would not be recognized
with the original method of Eskola et al. (6),
Surprising results were obtained with a pleural exti-
date and a serum pool of two different patients with
necrotizing pancreatitis: in both cases, specific and
unspecific binding were incomplete and showed great
variability. This observation might be explained by
the presence of a mixture of pancreatic and non-
pancreatic phospholipase A2 as already suggested by
Eskola et al. (6). The assay method described in this
article might help to confirm this hypothesis on a
larger collective.
In conclusion, the present method seems to be suitable
for experimental studies on the diagnostic and patho-
physiological role of phospholipase A2 isoenzymes in
patients with pancreatic and non-pancreatic diseases.
Our measurements support our previous assumption
(1 —4) that serum phospholipase A2 is not exclusively
derived from the pancreas. It will be of interest to use
the assay described in this article for further investi-
gation of these problems, as well as for a critical re-
evaluation of previous studies on the diagnostic and
prognostic value of phospholipase A2 in pancreatitis
which have been performed during the last three dec-
ades (24-27).
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